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Summary
— A synthesis of 2,4-bis-(4-amidinophenyl)pyrimidine 6, 2,4-bis-[(4-imidazolin-2-
yl)phenyl)]pyrimidine 7, 2,4-bis[(4-tetrahydropyrimidinyl-2-yl)phenyl]pyrimidine 8, 2,4-bis[(4-N-
n-propylamidino)phenyl]pyrimidine 9, 2,4-bis[(4-N-isopropylamidino)-phenyl]pyrimidine 10 and
2,4-bis[(4-N-isobutylamidino)phenyl]pyrimidine 11 starting from 4-bromobenzamidine and 4-
bromoaceto-phenone is reported. A synthesis of 2-(4-amidinophenyl)-4-(2-methoxy-4-
amidinophenyl)pyrimidine 20, 2-[4-(imidazolin2-yl)-phenyl]-4-[2-methoxy-4-(imidazolin-2-
yl)phenyl]pyrimidine 21, and 2-[4-(N-iso-propylamidino)phenyl]-4-[2-methoxy-4-(N-
isopropylamidino)phenyl]pyrimidine 22 beginning with 4-bromobenzamidine and 2-methoxy-4-
bromoacetophenone is described. Compounds 6–11 and 20–22 all bind strongly to DNA.
Compounds 6, 9–11, and 20 given at 5 mg/kg are more active and less toxic than pentamidine at
its effective dose when evaluated against Pneumocystis carinii pneumonia (PCP) in the
immunosuppressed rat model. Several compounds in this series are being evaluated further as
potential new anti-PCP agents.
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Introduction
Investigations from our laboratories have focused upon diaryldiamidines as dications which
exhibit both strong binding to DNA [1–4] and useful biological properties [5, 6]. The precise
mode of binding of these types of dicationic molcules with DNA has been found to be
extremely sensitive to structure and dramatic differences in binding mode and specificity
have resulted from relatively minor changes in structure [1–4]. The aromatic diamidines
berenil and stilbamidine exhibit strong minor-groove binding at sites which have three or
more consecutive AT base pairs [7, 9]. However, the well-known DNA stain DAPI, 2-[4′-
amidinophenyl]-6-amidinoindole, long known to bind in the minor groove of DNA at AT
sites, has also been found to intercalate at GC sites [2]. In a related study, the nucleic acid
binding properties of a series of 2,5-diphenylfuran dications were found to vary in
interaction with DNA from AT selective minor-groove binding, to classical intercalation at
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GC sites, to threading intercalation at GC sites, depending upon the intrinsic nature of the
cationic groups [3]. Recent reports [10, 11] have suggested that 2,5-bis[(4-
amidino)phenyl]furan also binds in the major groove of DNA in addition to binding in the
minor groove, however this view has been questioned [12]. The crystal structure of a
complex between 2,5-bis[(4-amidino)phenyl]furan and d(CGCGAATTCGCG)2 was
recently solved and clearly illustrates the minor-groove-binding mode [13]. A method of
calculating the radius of curvature of groove-binding molecules has been developed by Cory
et al [14], which expands upon the isohelicity concept [16]. Furthermore, the study
suggested that the curvature of the small molcule is an important factor in determining the
effectiveness of the interaction of groove-binding dications with DNA [14]. Cory et al
suggested that dicationic molcules with calculated radius of curvature values between 10
and 100 Å should effectively bind to the minor groove of DNA. We recently evaluated the
effect of structural modification on the nucleic acid binding of dicationic 2,4-
diarylpyrimidines which have calculated radius of curvature values of approximately 85 Å
[17]. The binding affinities of these dicationic 2,4-diarylpyrimidines were sensitive to steric
requirements and torsion angles of the cationic centers [17].
The binding of such dicationic molecules to the DNA minor groove has been associated
with the ability of these molecules to inhibit DNA-related enzymes such as topoisomerase II
[18]. Pentamidine and its analogs [19], dicationic bis-benzimidazoles [20, 21], and more
recently dicationic 2,5-diarylfurans [13] (the latter give calculated radius of curvature values
of approximately 15 Å) have been shown to be effective in treating Pneumocystis carinii
pneumonia (PCP) and topoisomerase II inhibition may be involved in their mode of action.
Collectively, these observations led us to evaluate dicationic 2,4-diarylpyrimidines, which
give radius of curvature values in the range predicted to be effective DNA binding agents
[17] and which have been demonstrated to strongly bind to AT-rich DNA [14], for
effectiveness against PCP. In this paper we describe the synthesis and biological activity of
several dicationic 2,4-diarylpyrimidines.
Chemistry
The synthetic route employed to make the dicationic pyrimidines is outlined in scheme 1.
The key intermediate, 2,4-bis(4-bromophenyl)pyrimidine 4, was obtained in good yield by
base-promoted condensation of 4-bromobenzamidine and 1-dimethylamino-3-
dimethylimmonio-1-(4-bromophenyl)-1-propene 3 using the approach described by Wagner
and Jutz [22]. The bisnitrile 5 was readily obtained by the action of copper(I) cyanide on 4
in refluxing DMF in a standard manner [23]. The bis-nitrile 5 was converted into the
corresponding imidate ester using applied Pinner methodology [24]. The dicationic molcules
6–11 were obtained by reacting the imidate ester with ammonia or the appropiate amine
using conventional approaches.
The monocationic 2-phenyl-4-[4-(imidazolin-2-yl)-phenyl]pyrimidine 15 was prepared to
serve as a control compound for the dicationic pyrimidines for studies of both their
interaction with DNA and their properties as anti-PCP agents. The method employed for
synthesis of 15 parallels that used for the preparation of the dicationic molcules and is
outlined in scheme 2.
The synthesis of the methoxy-substituted pyrimidines 20–22 is outlined in scheme 3. The
required 2-methoxy-4-bromoacetophenone was obtained by methylation of 4-bromo-2-
hydroxyacetophenone which was the product of the Fries rearrangement of 3-bromo-phenyl
acetate [25]. Pyrimidine ring formation was achieved by the base-promoted condensation
between 4-bromobenzamidine and 3-dimethylamino-1-(4-bromo-2-methoxyphenyl)prop-2-
ene-1-one 17. Conversion of 2-(4-bromophenyl)-4-(2-methoxy-4-bromophenyl)-pyrimidine
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18 into the corresponding bisnitrile 19 and thence on to the dicationic target compounds 20–
22 was achieved using the approach described above for the preparation of the parent 2,4-
diarylpyrimidine series.
Biological results and discussion
The results from the evaluation of the DNA binding characteristics and the in vivo anti-PCP
activity of the pyrimidines are recorded in table I. All of the dicationic pyrimidines
effectively bind to DNA as indicated by the ΔTm values recorded in table I. The ΔTm
differences between the parent series (6, 7) and the methoxy-substituted series (20, 21) have
been previously attributed to the effect of structural changes on the pyrimidine systems on
binding in the minor groove [17]. Variation of the alkyl group on an amidino nitrogen
causes some reduction in ΔTm values; compare values for 6 with those for 9–11.
Interestingly, the changes are smaller than noted for substitution effects on the aryl rings
[17]; compare values for 6, 10 and 20. As expected, the monocation 15 does not effectively
interact with DNA and it shows no activity against PCP in the immunosuppressed rat model.
Compound 8 exhibits the strongest interaction with DNA in this series; analogous results
have been noted for the tetrahydropyrimidine cationic center in other similar series of
dicationic molcules [20, 21]. There is no apparent direct relationship between topoisomerase
II inhibition, modeled using the enzyme from Gardia lamblia, and DNA binding or in vivo
anti-PCP activity. The dicationic pyrimidines 7 and 8, which have the amidine unit
incorporated in a five- and six-membered ring system, exhibit strong binding to DNA but
show only moderate activity in vivo against PCP at dosages of 5.0 and 2.5 mg/kg
respectively. Compound 8 was toxic at the 5 mg/kg dosage. Substitution on the amidine
group with a single alkyl group yields improved anti-PCP activity in the parent pyrimidine
system; compare the results for 9 and 10 to that of 6. Several of the dications including 6, 9–
11, and 20 screened at 5 mg/kg have comparable or improved anti-PCP activities compared
to pentamidine, tested at 10 mg/kg, with apparently reduced overt toxicity. Further studies




Melting points were recorded using a Thomas Hoover (Uni-Melt) capillary melting point
apparatus and are uncorrected. 1H-NMR and 13C-NMR spectra were recorded employing a
Varian VXR400 spectrometer and chemical shifts (δ) are in ppm relative to TMS; coupling
constants are in hertz. High resolution mass spectra were recorded with a VG Instruments
70-SE spectrometer (Georgia Institute of Technology, Atlanta, GA); others were recorded
by a Shimadzu GC-MS 5000 instrument at 70 eV chamber voltage on a direct inlet system.
IR spectra were recorded using a Michelson 100 (Bomem, Inc) instrument. Elemental
analysis were obtained from Atlantic Microlab Inc (Norcross, GA) and are within ±0.4% of
the theoretical values. All chemicals and solvents were purchased from Aldrich Chemical
Co or Fisher Scientific.
Chemistry
1-Dimethylamino-3-dimethylimmonio-1-(4-bromophenyl)-1-propene
perchlorate 3—To a cooled and stirred solution of dry DMF (73 g, 1.0 mol) in 150 mL
dry chloroform was added, drop wise, freshly distilled phosphorus oxychloride (122.8 g, 0.8
mol). The solution turned reddish pink during addition and was stirred for 1 h. 4-Bromo-
acetophenone (39.8 g, 0.2 mol) in 100 mL dry chloroform was added to the previously
prepared solution and the mixture was heated to 50–60 °C for 3 h. After the mixture was
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allowed to cool it was poured into stirred ice-cold water (external cooling required). The
aqueous solution was extracted with 100 mL ether, and aqueous dimethylamine (40% soln)
was added slowly with cooling to the aqueous layer. A thick yellow precipitate formed was
filtered and was resuspended in 200 mL water. A solution of sodium perchlorate (34 g, 0.28
mol) in 50 mL water was added to the suspension, and a thick yellow precipitate was
obtained. The precipitate was filtered and dried in vacuo at 50 °C for 12 h. The yellow solid
was dissolved in 400 mL boiling absolute ethanol. After cooling the off-white crystalline
precipitate was filtered, washed with dry ether and dried in vacuo at 50 °C for 24 h, to yield
50.5 g (66%) mp 160–162 °C. IR (KBr) 2931, 1630, 1561, 1394, 836 cm−1. 1H-NMR
(DMSO-d6) 7.76 (d. 2H. J = 8), 7.27 (d, 2H, J = 8), 6.91 (d, 1H, J = 12), 5.56 (d, 1H, J =
12), 3.31 (s, 3H), 3.13 (s, 3H), 3.11 (s, 3H), 2.87 (s, 3H). 13C-NMR (DMSO-d6) 169.4,
160.9, 131.9, 130.8, 130.5, 123.9, 91.8, 45.8, 42.8. 40.8, 38.1. MS m/e 281 (M+ – HClO4).
4-Bromobenzamidine—A stirred mixture of 4-bromobenzonitrile (36.4 g, 0.2 mol) and
ammonium benzenesulfonate (45 g, 0.26 mol) was gradually heated to 260–270 °C (bath
temperature) for 2.5 h; at this temperature the melt becomes a clear liquid (both boiling and
sublimation of the mixture is observed). The bath was removed and the melt was slowly and
carefully added to 600 mL acetone to dissolve unreacted nitrile and also to prevent the melt
from becoming a hard solid mass. Any lumps were broken and the solid was filtered. The
solid was thoroughly ground and then slurried with water to remove any excess ammonium
benzene sulfonate. The solid was slurried with acetone and filtered, washed with dry ether
and the gray-brown solid dried in vacuo at 100 °C for 12 h. The yield of 4-
bromobenzamidine benzenesulfonate was 33 g (51% based on recovered nitrile), mp 253 °C
(lit [28] 250–260 °C). The acetone extract yielded unreacted p-bromobenzonitrile (12.8 g).
IR (KBr) 3325, 3126, 1681, 1597 cm−1. 1H-NMR (DMSO-d6) 9.15 (s, 4H), 7.8 (q, 4H),
7.32 (m, 2H), 7.23 (m, 3H). 13C-NMR (DMSO-d6) 164.8, 147.8, 131.9, 130.0, 128.4, 127.5,
127.2, 125.3.
To a stirred mixture of 4-bromobenzamidine benzenesulfonate (3.57 g, 0.01 mol) in 10 mL
water was added 6–7 mL 5 M NaOH and stirring was maintained for 10 min; the solid was
filtered, washed with water, dissolved in acetone (50 mL), treated with charcoal, filtered and
the acetone removed under reduced pressure. The white crystalline solid obtained was
washed with dry ether and dried in vacuo at 40 °C (12 h). Yield: 1.5 g (75%), mp 168–169
°C (lit [28] 159 °C). IR (KBr) 3420, 3326, 3240, 3050, 1649 cm−1. 1H-NMR (DMSO-d6, 45
°C) 7.74 (d, 2H, J = 8.2), 7.62 (d, 2H, J = 8.2), 6.43 (br, 3H). 13C-NMR (DMSO-d6, 45 °C)
161.3, 135.4. 130.7, 128.5, 123.0. MS m/e 198 (M+).
2,4-Bis(4-bromophenyl)pyrimidine 4—To a stirred mixture of p-bromobenzamidine
benzenesulfonate (10.7 g, 0.03 mol) and 1-dimethylamino-3-dimethylimmonio-1-(4-
bromophenyl)-1-propene perchlorate (8.4 g, 0.022 mol) in 100 mL absolute ethanol was
added 0.055 mol sodium ethoxide (prepared from 1.26 g Na and 70 mL ethanol). After
stirring for 30 min at room temperature a further equivalent of sodium ethoxide was added
and the mixture was heated under reflux with efficient stirring for 3 h. The solvent was
removed under reduced pressure, and the yellow residue was triturated with 100 mL water.
The resulting solid was filtered and washed with water. The yellow cake, after drying, was
recrystallized from ether/hexane (2:3) to give colorless needles, 7.37 g (86% yield), mp
165–166 °C. IR (KBr) 1585, 1578, 1555, 816, 765 cm−1. 1H-NMR (CDC13, 35 °C) 8.71 (d,
1H, J = 5.5), 8.39 (d, 2H, J = 8.5), 8.25 (d, 2H, J = 8.5), 7.63 (d, 2H, J = 6.7), 7.6 (d, 2H, J
= 6.7), 7.5 (d, 1H, J = 5.5). 13C-NMR (CDCl3, 35 °C) 163.9, 162.8, 158.0, 136.7, 135.7,
132.2, 131.7, 129.9, 128.6, 125.8, 125.6, 114.3. MS m/e 390 (M+).
2,4-Bis(4-cyanophenyl)pyrimidine 5—A mixture of 2,4-bis(4-
bromophenyl)pyrimidine (7.8 g, 0.02 mol) and copper(I) cyanide (4.45 g, 0.05 mol) in 50
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mL dry DMF was heated under reflux for 30–35 h, during which time the color changed to
dark brown. When the mixture was poured into 300 mL ice-cold water, a brown solid
precipitated. The mixture was stirred for 3 h with 300 mL 10% NaCN solution; the solid was
filtered, washed with water (1.5 L) and dried. The brown solid cake was placed in a soxhlet
device and treated with acetone for 36 h. The solvent was removed and the light brown solid
was chromatographed over neutral Al2O3. Elution with acetone/hexane (7:3) (20 × 50 mL
fractions) and evaporation of the solvent yielded pale yellow fluffy needles which were
dried in vacuo at 100 °C (6–7 h). Yield: 2.7 g (48%), mp 239–241 °C. IR (KBr) 2223, 1580,
1550, 831, 798 cm−1. 1H-NMR (DMSO-d6, 35°C) 9.08 (d, 1H, J = 5.4), 8.65 (d, 2H, J=
8.8), 8.5 (d, 2H, J = 8.3), 8.15 (d, 2H, J = 5.4), 8.03 (d, 2H, J = 8.8), 8.01 (d, 2H, J =
8.3). 13C-NMR (DMSO-d6, 35 °C) 161.7, 161.2, 159.0, 140.8, 139.8, 139.6, 132.6, 132.3,
128.2, 127.7, 118.2, 118.0, 116.3, 113.4, 113.1. MS m/e 282 (M+). Anal C18H10N4 (C, H,
N).
2,4-Bis-(4-amidinophenyl)pyrimidine trihydrochloride 6—The bisnitrile 5 (2.8 g,
0.011 mol) was suspended in 250 mL absolute ethanol, cooled in an ice–salt bath and dry
HCl gas was passed through it; the compound dissolved. The clear yellow solution was
placed in a pressure bottle and left for 12 h with occasional shaking. The imidate ester
hydrochloride which formed was filtered, washed with dry ether and dried in vacuo to yield
4.2 g. The dried imidate ester was shown to be free of contamination by the bisnitrile
starting material by its IR spectrum.
Dry ammonia was passed through a cold suspension of 2.1 g (0.0043 mol) of imidate ester
in 50 mL absolute ethanol until saturated. The mixture was shaken for 2 days; the solvent
was removed, and the resulting solid was suspended in water and basified to pH > 9 with 2
M NaOH. The free base of 6 precipitated, was filtered and dried in vacuo at 70 °C for 12 h.
The off-white solid was recrystallized from boiling ethanol. Yield: 1.1 g (69%), mp 237–239
°C (dec). IR (KBr) 3459, 3349, 3251, 1649, 1583 cm−1. 1H-NMR (CD3CO2D, 70 °C) 9.05
(d, 1H, J = 5.4), 8.71 (d, 2H, J = 8.8), 8.49 (d, 2H, J = 8.8), 8.08 (d, 2H, J = 8.8). 13C-NMR
(CD3CO2D, 70 °C) 167.5, 167.3, 164.2, 163.8, 160.0, 143.7, 142.8, 131.4, 131.0, 130.1,
129.7, 129.3, 129.2, 117.5. MS m/e 316 (M+). FAB m/e 317 (M+ + H). Anal
C18H16N6·0.5H2O (C, H, N).
The free base of 6 (0.8 g, 0.0025 mol) was suspended in 25 mL absolute ethanol, 25 mL
saturated ethanolic HCl was added and the mixture was allowed to reflux for 1 h. After
cooling, the volume was reduced to 15 mL. The off-white solid that formed was filtered and
washed with dry ether. The salt was dried in vacuo at 80 °C for 24 h. Yield: 1.0 g (94%), mp
>360 °C (sublimes). IR (KBr) 3356, 3249, 3007, 1684, 1609 cm−1. 1H-NMR (D2O/TSP/50
°C) 8.43 (d, 1H, J = 5.4), 7.87 (d, 2H, J = 7.8), 7.81 (d, 2H, J = 7.8), 7.57 (d, 4H, J = 7.8),
7.44 (d, 1H, J = 5). 13C-NMR (D2O/TSP/50 °C) 162.3, 162.2, 158.9, 158.3, 155.0. 137.8,
137.0, 126.5, 126.1, 125.7, 125.3, 125.1, 125.0, 113.4. MS FAB m/e 317 (M+ + H). Anal
C18H16N6·3HCl (C, H, N).
2,4-Bis[(4-imidazolin-2-yl)phenyl]pyrimidine hydrochloride 7—The bis-imidate
ester hydrochloride from 5 (2.1 g, 0.0043 mol) was suspended in 50 mL absolute ethanol,
ethylene diamine (0.6 g, 0.01 mol) was added and the mixture was refluxed for 12 h. The
solvent was evaporated and the resulting solid triturated with water. The off-white solid thus
obtained was filtered, washed with water and dried. After treating with NaOH the resultant
free base of 7 was boiled with 800 mL absolute ethanol and filtered to yield a beige
crystalline solid. Yield: 1.3 g (82%), mp 337–339 °C (dec) (turns brown at 320 °C and black
at mp). IR (KBr) 3190.2, 1615.4, 1602.6, 1575.8 cm−1. 1H-NMR (CD3CO2D) 65 °C 9.04
(d, 1H, J = 5.4), 8.72 (d, 2H, J = 8.3), 8.49 (d, 2H, J = 8.8), 8.16 (d, 2H, J = 8.3), 8.1 (d, 2H,
J = 8.8), 7.98 (d, 1H, J = 5.4), 4.19 (s, 8H). 13C-NMR (CD3CO2D) 65 °C 167.02, 166.8,
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163.9, 163.6, 144.1, 143.0, 139.4, 130.4, 130.1, 130.0, 129.2, 125.5, 125.1, 117.6, 46.1. MS
EI (electron capture) 368.2 (M+). Anal C22H20N6 (C, H, N).
The free base of 7 (1.0 g, 0.0027 mol) was suspended in 35 mL saturated ethanolic HCl and
allowed to reflux for 1 h (not all the solid dissolved). The solvent was reduced, in vacuo, to a
volume of to 5–6 mL, diluted with dry ether and filtered, washed with dry ether and dried in
vacuo at 100 °C 24 h. Yield: 1.2 g, mp > 360 °C. IR (KBr) 3405, 3060, 2945, 1618, 1607,
1572 cm−1. 1H-NMR (D2O/dioxane 45 °C) 8.73 (d, 1H, J = 5.5), 8.13 (d, 2H, J = 7.9), 8.03
(d, 2H, J = 7.9), 7.71 (m, 5H), 4.02 (s, 4H), 4.01 (s, 4H). 13C-NMR (D2O/dioxane/45 °C)
164.7, 164.5, 161.2, 158.3, 141.2, 140.2, 128.4, 128.2, 127.7, 123.6, 123.3, 116.2, 44.5. MS
EI m/e 368.2 (M+). Anal C22H20N6·3HCl·1.5H2O (C, H, N).
2,4-Bis[(4-tetrahydropyrimidinyl-2-yl)phenyl]pyrimidine hydrochloride 8—
Reaction of the bisimidate ester hydrochloride from 5 with 1,3-propanediamine as described
above for 7 gave a 53% yield of the free base of 8, mp 165–166 °C. IR (KBr) 3350, 3179,
3035, 2945, 1633, 1575, 1438, 1367, 1197, 832, 695 cm−1. 1H-NMR (DMSO-d6, 35 °C)
8.96 (d, 1H, J = 5.4), 8.52 (d, 2H, J = 8.3), 8.35 (d, 2H, J = 8.3), 8.04 (d, 2H, J = 5.4), 7.95
(d, 2H, J = 8.3), 3.41–3.37 (m, 8H), 1.73–1.72 (m, 4H). 13C-NMR (DMSO-d6, 35 °C) 162.9,
162.4, 158.6, 153.1, 152.7, 138.8, 138.2, 138.1, 136.8, 127.4, 126.7, 126.4, 115.3, 41.4,
41.3, 20.4, 20.3. MS m/e 396 (M+).
The free base of 8 was converted into 8 (mp 267–268 °C) as described above for 7 in an
82% yield. IR (KBr) 3425, 3179, 3025, 1640, 1620, 1574, 1400, 1013, 832, 693 cm−1. 1H-
NMR (DMSO-d6/45 °C) 10.5 (s, 2H), 10.43 (s, 2H), 9.08 (d, 1H, J = 5.4), 8.68 (d, 3H, J =
8.3), 8.55 (d, 2H, J = 8.3), 8.21 (d, 1H, J = 5.4), 8.08 (d, 2H, J = 8.4), 8.03 (d, 2H, J = 8.8),
3.52 (m, 6H), 2.0 (m, 4H). 13C-NMR (DMSO-d6/40 °C) 162.2, 161.7, 159.2, 158.5, 158.3,
141.0, 139.9, 130.5, 130.3, 128.5, 128.2, 128.0, 127.4, 116.44, 38.9, 17.6. Anal
C24H24N6·3HCl·0.5H2O (C, H, N).
2,4-Bis[(4-N-n-propylamidino)phenyl]pyrimidine dihydrochloride 9—Freshly
distilled n-propylamine (0.265 g, 0.0045 mol) was added to a suspension of the imidate ester
from 5 (0.73 g, 0.0015 mol) in 15 mL ethanol and stirred under nitrogen at room
temperature for 12 h. The solvent was removed under vacuum, and the residue was triturated
with dry ether and decanted. The residue was dissolved in cold water (20 mL) and basified
with 2 M NaOH which led to the precipitation of the free base of 9. The solid was filtered,
washed with water, dried, and dissolved in CHC13. The solution was dried over Na2SO4, the
volume was reduced under vacuum and the solid was collected by filtration.
Recrystallization from CHCl3/ether gave an off-white solid (0.5 g, 83%), mp 182–183
°C. 1H-NMR (DMSO-d6) 8.97 (d, 1H, J = 5.4), 8.51 (d, 2H, J = 8.4), 8.34 (d, 2H, J = 5.4),
8.03 (d, 1H, J = 5.4), 7.93 (t, 4H), 6.38 (br, 4h), 3.12 (t, 4H, J = 7.2), 0.97 (t, 6H, J = 7.2).
MS m/e 380 (M+).
Ethanol saturated with hydrogen chloride (5 mL) was added to a solution of 0.4 g (0.001
mol) of the free base of 9 in 10 mL ethanol, stirred at 60 °C for 16 h and the solvent
removed under vacuum to yield a solid. The solid was triturated with dry ether, filtered,
dried under vacuum at 80 °C for 24 h to yield 0.43 g (89 %), mp 228–231 °C. IR (KBr)
3410, 3330, 3190, 2950, 1663, 1600, 1570, 1380, 1115 cm−1. 1H-NMR (DMSO-d6) 10.33
(s, 1H), 10.27 (s, 1H), 9.81 (s, 1H), 9.8 (s, 1H), 9.47 (s, 1H), 9.07 (d, 1H, J = 5.4), 8.63 (d,
2H, J = 8.7), 8.51 (d, 2H, J = 8.2), 8.2 (d, 1H, J = 5.4), 8.06 (t, 4H, J = 8.7), 3.51 (brq, 4H. J
= 6.3), 1.72 (sext, 4H, J = 7.2). 1.0 (t, 6H, J = 7.2). 13C-NMR (DMSO-d6) 162.1, 161.9,
159.0, 141.0, 139.9, 130.9, 130.7, 128.8, 128.6, 127.7, 127.1, 116.3, 44.1, 20.6, 10.8. Anal
C24H28N6·2HCl·0.5H2O (C, H, N).
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2,4-Bis[(4-N-isopropylamidino)phenyl]pyrimidine hydrochloride 10—Reaction of
isopropylamine with the bisimidate ester hydrochloride from 5 as described above for 9 gave
a 71% yield of the free base of 10, mp 198–199 °C. IR (KBr) 3352, 3020, 2930, 1620, 1571,
1380 cm−1. 1H-NMR (DMSO-d6/D2O) 9.01 (d. 1H, J = 5.37), 8.59 (d. 2H, J = 8.3), 8.40 (d,
2H, J = 8.3), 8.06 (d, 1H, J = 5.37), 7.89 (d, 2H, J = 7.3), 7.86 (d, 2H, J = 7.81), 3.92 (sept,
2H, J = 6.35), 1.25 (d, 6H, J = 6.35), 1.24 (d, 6H, J = 6.35). MS m/e 400 (M+).
The free base of 10 was converted into 10 (mp 258–260 °C) as described above for 9 in an
83% yield. IR (KBr) 3420, 3348, 3221, 2988, 1670, 1618, 1573, 1437,1392, 1128 cm−1. 1H-
NMR (D2O/DMSO-d6) 9.86 (brt, 2H, J = 10.2, J = 8.3), 9.68 (brd, 2H, J = 8.77), 9.41 (brd,
2H, J = 8.3), 9.1 (d, 1H, J = 5.37), 8.67 (d, 2H, J = 8.3), 8.53 (d, 2H, J = 8.3), 8.22 (d, 1H, J
= 5.37), 7.98 (t, 4H, J = 7.8), 4.2 (sept. 2H, J = 8.35), 1.32 (d, 12H, J = 6.35). 13C-NMR
(D2O/DMSO-d6) 162.3, 161.8, 161.3, 161.1. 159.2, 141.0, 139.9, 131.4, 131.1,129.1, 128.8,
127.2, 116.4, 45.2, 21.1. Anal C24H28N6·2HCl·0.5H2O (C, H, N).
2,4-Bis[(4-N-isobutylamidino)phenyl]pyrimidine dihydrochloride 11—Reaction
of isobutylamine with the bisimidate ester hydrochloride from 5 as described above for 9
gave a 86% yield of the free base of 11, mp 190–192 °C. IR (KBr) 3384, 3234, 3032, 2952,
1672, 1627, 1564, 1437, 1387, 1180 cm−1. 1H-NMR (DMSO-d6/D2O) 9.05 (d, 1H, J =
5.37), 8.61 (d, 2H, J = 8.3), 8.45 (d, 2H, J = 8.3), 8.13 (d, 1H, J = 5.37), 7.97 (t, 4H, J =
8.3). MS m/e 428 (M+).
The free base of 11 was converted into 11 (mp 240–242 °C dec) as described above for 9 in
an 90% yield. IR (KBr) 3420, 3219, 3056, 2955, 2864, 1672, 1624, 1573. 1438, 1016
cm−1. 1H-NMR (DMSO-d6) 10.16–10.07 (brm, 2H), 9.73(s, 1H), 9.70 (s, 1H), 9.39 (s, 1H),
9.36 (s, 1H). 9.12 (d, 1H. J = 5.37), 8.69 (d, 2H, J = 8.79), 8.56 (d, 2H. J = 8.79), 8.23 (D,
1H, J = 8.79), 8.02 (t, 4H, J = 8.3), 3.34 (d, 4H), 3.08 (sept, 2H, J = 6.35), 1.0 (d, 12H, J =
6.35). 13C-NMR (DMSO-d6) 162.7, 162.4, 162.3, 161.8, 159.2, 141.1, 140.0, 131.2, 130.9,
128.9, 128.7, 127.9, 127.3, 116.5, 49.6, 26.9, 19.7. Anal C26H33N6·2HCl·H2O (C, H, N).
2-Phenyl-4-(4-bromophenyl)pyrimidine 13—Benzamidine hydrochloride and 1-
dimethylamino-3-dimethyl-immino-1-(4-bromophenyl)-1-propene perchlorate 3 were
allowed to react as described above for the preparation of 4. After work-up and
recrystallization from CHCl3 ethyl ether (1:3), 72% yield of a white crystalline solid was
obtained, mp 107–108 °C. IR (KBr) 2925, 1597, 1562, 1540, 1427 cm−1. 1H-NMR (CDCl3)
8.65 (d, 1H, J = 5.3). 8.55–8.52 (m, 2H), 8.02 (d, 2H, J = 8.3), 7.6 (d, 2H, J = 8.8), 7.5–7.46
(m, 3H), 7.44 (d, 1H, J = 5.3). 13C-NMR (CDCl3) 164.6, 162.5, 157.9, 137.6, 135.7, 132.1,
130.8, 128.6, 128.5, 128.2, 125.6, 114.1. MS m/e 311 (M+).
2-Phenyl-4-(4-cyanophenyl)pyrimidine 14—2-Phenyl-4-(4-bromophenyl)pyrimidine
13 was converted into 14 as described above for 5 to give, after recrystallization from
CHCl3/ethyl ether (1:3), a white crystalline solid in a 55% yield, mp 125–126 °C. IR (KBr)
2235, 2277, 1592, 1562, 1425 cm−1. 1H-NMR (DMSO-d6/90 °C) 9.0 (d, 1H, J = 5.3), 8.5–
8.45 (m, 2H), 8.4 (d, 2H. J = 8.3), 8.04 (d, 1H, J = 5.3), 8.01 (d, 2H, J = 8.8), 7.55–7.53 (m,
3H). 13C-NMR (DMSO-d6/90°C) 163.4, 161.0, 159.0, 140.0, 136.9, 132.8, 130.9, 128.6,
127.8, 118.3, 115.7, 113.3. MS m/e 257 (M+).
2-Phenyl-4-(4-imidazolin-2-yl)phenylpyrimidine hydrochloride 15—The imidate
ester from 14 was allowed to react with ethylene diamine as outlined above for 7 and a 70%
yield of the free base of 15 (white solid, recrystallization from ethanol, mp 200–202 °C) was
obtained. IR (KBr) 3176, 2925, 2865, 1606, 1562, 1422 cm−1. 1H-NMR (CDCl3/40 °C) 8.84
(d, 1H. J = 5.5), 8.8–8.55 (m, 2H), 8.25 (d, 2H, J = 8.6), 7.95 (d, 2H, J = 8.6), 7.6 (d, 1H, J
= 5.5), 3.83 (s, 4H). 13C-NMR (DMSO-d6/50 °C) 163.3, 162.9, 162.1, 158.5, 139.7, 137.5,
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137.1, 132.9, 130.6, 128.4, 127.7, 127.5, 126.7, 115.0, 49.5. MS m/e 299 (M+). The free
base of 15 was converted into the hydrochloride salt by the standard procedure to yield a
white solid (85%, mp > 300 °C). IR (KBr) 3033, 2876, 2710, 1607, 1587 cm−1. 1H-NMR
(DMSO-d6/50 °C) 11.25 (s, 2H), 8.95 (d, 1H, J = 5.5), 8.54–8.44 (m, 2H), 8.52 (d, 2H, J =
8.6), 8.37 (d, 2H, J = 8.6), 8.15 (d, 1H, J = 5.5), 7.75 (s, 1H. NH), 7.55–7.53 (m, 3H), 4.02
(s, 4H). 13C-NMR (DMSO-d6/50 °C) 163.9, 163.3, 161.1, 158.7, 141.2, 136.8, 130.7, 129.4,
128.4, 127.7, 127.3, 124.0, 115.6, 44.2. Anal C19H15N4·2HCl·0.5H2O (C, H, N).
2(4-Bromophenyl)-4-(2-methoxy-4-bromophenyi)pyrimidine 18—Reaction of 3-
dimethylamino-1-(4-bromo-2-methoxyphenyl) propenone and 4-bromobenzamidine as
described above for 4 yielded an off-white crystalline solid (62%), mp 153–155 °C. IR
(KBr) 3040, 2920, 1592, 1560, 1433, 1387, 1235, 1039, 859, 807 cm−1. 1H-NMR (CDC13)
8.74 (d, 1H, J = 5.4), 8.39 (d, 2H, J = 8.8), 8.10 (d, 1H, J = 8.3), 7.83 (d, 1H, J = 5.4), 7.61
(d, 2H, J = 8.3), 7.28 (dd, 1H, J = 1.95), 7.17 (s, 1H), 3.91 (s, 3H). 13C-NMR (CDCl3)
163.4, 161.6, 158.6, 157.1, 136.9, 132.3, 131.7, 129.7, 125.7, 125.3, 125.1, 124.4, 119.6,
115.1, 55.9. MS m/e 420 (M+).
2-(4-Cyanophenyl)-4-(2-methoxy-4-cyanophenyl)pyrimidine 19—Reaction of the
dibromo compound 18 as described above for 5 yielded a white solid (40%), mp 239–240
°C. IR (KBr) 3085, 2229, 1579, 1556, 1406, 1274, 1027, 819 cm−1. 1H-NMR (CDCl3) 8.88
(d, 1H, J = 4.4), 8.65 (d, 2H, J = 8.3), 8.3 (d, 2H, J = 8.3), 7.94 (d, 1H, J = 4.4), 7.79 (d, 2H,
J = 8.3), 7.46 (dd, 1H, J = 8.3, J = 1.4), 7.3 (s, 1H), 3.99 (s, 3H). 13C-NMR (CDCl3) 162.9,
161.0, 158.1, 157.6, 141.7, 132.3, 132.0, 130.5, 124.9, 120.6, 118.7, 118.2, 115.0 114.2,
56.2. MS m/e 312 (M+). Anal C19H12N4O (C, H, N).
2-(4-Amidinophenyl)-4-(2-methoxy-4-amidinophenyl)pyrimidine
trihydrochloride 20—The dinitrile 19 was converted into the free base of 20 as described
above for 6 to yield a white crystalline solid (73%), mp 148–149 °C dec. IR (KBr) 3380,
3290, 3212, 1645, 1570, 1420, 1256, 1185, 1026, 829 cm−1. 1H-NMR (DMSO-d6/D2O)
8.84 (d, 1H, J = 4.4), 8.42 (d, 2H, J = 8.4), 8.09 (d, 1H, J = 4.4), 7.9 (d, 1H, J = 5.2), 7.66 (d,
2H, J = 8.4), 7.53 (brs, 1H), 7.47 (d, 1H, J = 8.8). 13C-NMR (DMSO-d6/D2O) 163.8, 163.5,
163.3, 162.2, 158.3, 158.2, 139.8, 139.4, 138.2, 131.1, 128.2, 127.6, 127.3, 120.5, 119.7,
111.1, 56.5. MS m/e 346 (M+).
The free base of 20 was converted into the trihydrochloride salt of 20 (mp 255–257 °C dec)
as described above for 6 in a 75% yield. IR (KBr) 3380, 3270, 3137, 1677, 1597, 1257,
1019, 735 cm−1. 1H-NMR (DMSO-d6) 9.79 (s, 2H), 9.65 (s, 2H), 9.49 (s, 2H), 9.44 (s, 2H),
9.0 (d, 1H, J = 6.8), 8.6 (d, 2H, J = 8.4), 8.25 (d, 1H, J = 8.0), 8.04 (m, 3H), 7.77 (s, 1H),
7.67 (d, 1H, J = 8.0). 13C-NMR (DMSO-d6) 165.4, 164.9, 162.1, 161.0, 158.2 157.6, 141.8,
131.1, 130.9, 129.8 129.7, 128.7, 128.0, 120.7, 120.5, 112.4, 56.6. Anal
C19H18N6O·3HCl·1.5H2O (C, H, N).
2-(4-[Imidazolin-2-yl]phenyl)-4-(2-methoxy-4-[imidazolin-2-yl]-
phenyl)pyrimidine 21—Reaction of the bisimidate ester hydrochloride from 19 with 1,2-
ethanediamine as described above for 7 gave a 74% yield of the free base of 21, mp 150–
151 °C. IR (KBr) 3375, 3214, 2938, 2866, 1606, 1567, 1429, 1275, 1233, 1027. 986
cm−1. 1H-NMR (DMSO-d6/45 °C) 8.93 (d, 1H, J = 5.4), 8.51 (d, 2H, J = 8.3), 8.21 (d, 1H, J
= 7.8), 8.0 (d, 2H, J = 7.8), 7.98 (d, 1H, J = 2.4), 7.67 (s, 1H), 7.63 (d, 2H, J = 7.8), 3.97 (s,
3H), 3.67 (s, 4H), 3.65 (s, 4H). 13C-NMR (DMSO-d6/45 °C) 163.2, 163.0, 162.7, 161.4,
157.6, 157.5, 138.8, 134.0, 132.50, 130.3, 127.4, 127.3, 126.7, 119.7, 119.5 110.8, 55.8,
49.5. MS m/e 398 (M+).
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The free base of 21 was converted into the salt of 21 (mp 237–240 °C dec) by the standard
method in an 84% yield. IR (KBr) 3361 (br), 3113, 1617, 1590, 1258, 1024, 791 cm−1. 1H-
NMR (D2O/DMSO-d6/45 °C) 8.78 (d, 1H, J = 4.9), 8.32 (d, 2H, J = 6.9), 8.08 (d, 1H, J =
5.8), 7.98 (d, 1H, J = 5.3), 7.88 (d, 2H, J = 6.8), 7.44 (d, 1H, J = 8.3), 7.42 (s, 1H), 4.1 (s,
4H), 4.08 (s, 4H). 13C-NMR (D2O/DMSO-d6) 166.3, 166.0, 162.7, 162.0, 159.6, 159.0,
143.2, 132.8, 130.8, 129.8, 126.1, 124.8, 122.1, 121.7, 112.8, 57.5, 45.9. Anal
C23H22N6·3HCl· 1.5H2O (C, H, N).
2-(4-[N-Isopropylamidino]phenyl)-4-(2-methoxy-4-[N-
isopropylamidino]phenyl)pyrimidine 22—Reaction of isopropylamine with the
bisimidate ester hydrochloride from 19 as described above for 10 gave a 75% yield of the
free base of 22, mp 179–180 °C. IR (KBr) 3257, 3058, 2966, 1597, 1566, 1429, 1386, 1251,
1183, 801 cm−1. 1H-NMR (DMSO-d6/D2O) 8.9 (d, 1H, J = 4.9), 8.46 (d, 2H, J = 8.5), 8.12
(d, 1H, J = 8.5), 7.94 (d, 1H, J = 5.5), 7.85 (d, 2H, J = 8.5), 7.48 (s, 1H), 7.46 (d, 1H, J =
4.9), 3.96 (s, 3H) 3.82 (brm, 2H), 1.15 (d, 6H, J = 6.7), 1.13 (d, 6H, J = 6.1). 13C-NMR
(DMSO-d6/D2O) 162.8, 161.6, 157.5, 157.2, 157.1, 141.0, 139.3, 138.2, 130.0, 127.2, 126.8,
126.0, 119.5, 119.1, 110.4, 55.8, 43.7, 22.8. MS m/e 430 (M+).
The free base of 22 was converted into 22 (mp 224–226 °C) by the standard approach to
give a 79% yield. IR (KBr) 3422, 3218, 3068, 1667, 1619, 1571, 1394, 1264, 1129, 1003,
738 cm−1. 1H-NMR (D2O/DMSO-d6/45 °C) 8.95 (d, 1H, J = 5.4), 8.55 (d, 2H, J = 8.3), 8.18
(d, 1H, J = 8.79), 8.0 (d, 1H, J = 5.4), 7.83 (d, 2H, J = 8.3), 7.45 (s, 1H), 7.44 (d, 1H, J =
5.4), 3.96 (br, 2H), 3.89 (s, 3H), 1.29 (d, 6H), 1.27 (d, 6H). 13C-NMR (D2O/DMSO-d6/45
°C) 163.0, 162.4, 162.1, 158.9, 158.3, 142.0, 132.74, 131.9, 131.5, 130.1, 129.3, 128.8,
121.4, 121.2, 112.6, 57.0, 46.0, 46.0, 21.6. Anal C25H30N6O·3HCl·H2O (C, H, N).
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a) DMF, POCl3; b) (CH3)2NH; c) p-bromobenzamidine, NaOEt, EtOH; d) CuCN, DMF; e)
HCl, EtOH; f) NH3, NH2CH2CH2NH2, NH2CH2CH2CH2NH2, NH2-n-Pr, NH2-iPr or NH2-
iBu.
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a) NaOEt; b) CuCN, DMF; c) HCl, EtOH; d) NH2CH2CH2NH2.
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a) (CH3O)2CHN(CH3)2; b) p-bromobenzamidine, NaOEt, EtOH; c) CuCN, DMF; d) HCl,
EtOH; e) NH3, NH2CH2CH2NH2, or NH2-iPr.
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